Genpharmasec Ltd (531592)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- Q2 FY27, தாக்கல் செய்யப்பட்டது 3 நவ. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 28 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
Genpharmasec Ltd reported Q2 FY27 results on 3 Nov 2026: revenue ₹85.7 Cr (+162.4% year on year, +72.3% on the previous quarter), and net profit ₹1.0 Cr (against a loss a year earlier); the operating margin was 1.9%.
| Q2 FY27 (₹ கோடி) | மதிப்பு | YoY Q2 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹85.7 | +162.4% | +72.3% |
| செயல்பாட்டு லாபம் | ₹1.6 | நஷ்டத்திலிருந்து | +71.4% |
| நிகர லாபம் | ₹1.0 | நஷ்டத்திலிருந்து | நஷ்டத்திலிருந்து |
| EPS (₹) | 0.01 | நஷ்டத்திலிருந்து | — |
| செயல்பாட்டு லாப வரம்பு | 1.9% | — | — |
- திருப்பம்: ஓராண்டுக்கு முன் நஷ்டத்திற்கு மாறாக லாபம்
- செயல்பாட்டு லாப வரம்பு 333 bps YoY அதிகரித்தது
- வரிக்கு முந்தைய லாபத்தில் 67% மற்ற வருமானம் மற்றும் ஒருமுறை கிடைத்த வருமானங்களிலிருந்து வந்தது.
- லாபம் இருந்தும் FY26-இல் செயல்பாட்டுப் பணப்புழக்கம் எதிர்மறையாக இருந்தது
- மார். 2026 முதல் கடன்கள் 32% குறைந்துள்ளன
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹1.6 கோடி லாபத்தில், ₹0.5 கோடி (33%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது.
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Genpharmasec Ltd submitted its quarterly statement of deviation or variation for the quarter ended September 30, 2026, confirming no deviation in the utilization of funds raised via its Rights Issue. The total amount raised on February 21, 2024, was ₹4,845.05 lakh. The funds have been allocated towards acquiring equity shares of Derren Healthcare Private Limited (₹1,443.58 lakh fully utilized), debt repayment (₹289.00 lakh utilized out of ₹588.00 lakh), and working capital (₹1,650.00 lakh fully utilized). The Audit Committee reviewed the statement with no adverse comments.
- Zero deviation reported in the use of Rights Issue proceeds of ₹4,845.05 lakh as of September 30, 2026.
- Fully utilized ₹1,443.58 lakh for acquiring equity shares of Derren Healthcare Pvt Ltd to make it a subsidiary.
- Utilized ₹289.00 lakh towards debt repayment against an original allocation of ₹588.00 lakh.
- Fully utilized ₹1,650.00 lakh allocated for working capital needs.
Genpharmasec's board approved the total disinvestment of its wholly owned subsidiary Clinigenome India Private Limited to Micro Genomics India Private Limited. Clinigenome contributed Rs 100.47 lakh (0.72% of consolidated turnover) and a negative net worth of Rs 154.41 lakh during the last financial year. The sale agreement is yet to be entered, consideration is under negotiation, and closing is targeted on or before March 31, 2027. Additionally, Company Secretary Hardik Makwana resigned effective November 16, 2026.
- Clinigenome India turnover was Rs 100.47 lakh, representing 0.72% of consolidated turnover
- Target subsidiary had a negative net worth contribution of Rs 154.41 lakh (2.35%)
- Sale transaction is slated for completion on or before March 31, 2027
- Company Secretary & Compliance Officer Hardik Makwana resigns effective November 16, 2026
Genpharmasec Ltd reported consolidated revenue of ₹85.66 Cr for Q2 FY27 (quarter ended Sep 30, 2026), up 162% YoY from ₹32.64 Cr in Q2 FY26 and 72% QoQ from ₹49.71 Cr. Consolidated Profit Before Tax reached ₹1.58 Cr compared to a loss of ₹0.80 Cr in Q2 FY26. Additionally, the Board approved the complete disinvestment of wholly owned subsidiary Clinigenome India Pvt Ltd to Micro Genomics India Pvt Ltd by March 31, 2027. Clinigenome contributed ₹1.00 Cr (0.72%) to FY26 turnover with negative net worth of ₹1.54 Cr. Company Secretary Hardik Makwana also resigned, effective November 16, 2026.
- Q2 FY27 consolidated revenue jumped to ₹85.66 Cr from ₹32.64 Cr in Q2 FY26, driven by Pharmaceutical Trading (₹81.55 Cr)
- Turnaround in consolidated PBT to ₹1.58 Cr in Q2 FY27 versus a loss of ₹0.80 Cr in Q2 FY26
- Divestment of 100% stake in subsidiary Clinigenome India Pvt Ltd approved, expected by March 31, 2027
- Clinigenome contributed ₹100.47 Lakhs (0.72%) to FY26 turnover and has a net worth of negative ₹154.41 Lakhs
- Company Secretary & Compliance Officer Hardik Makwana resigned effective November 16, 2026
Promoter Rajesh Mirchumal Sadhwani acquired 50,00,000 equity shares (0.90% of total voting capital) of Genpharmasec Ltd through open market purchase on August 28, 2026. Following this transaction, his personal holding increased from 13.18% (7,30,00,000 shares) to 14.09% (7,80,00,000 shares). Total promoter group holding (including PAC Sneha Sadhwani) increased from 29.98% (16,60,01,000 shares) to 30.88% (17,10,01,000 shares). The total paid-up equity share capital remains unchanged at Rs 55.37 Cr divided into 55,37,19,700 equity shares of Re. 1 each.
- 50,00,000 shares (0.90% stake) acquired by promoter Rajesh Sadhwani via open market on August 28, 2026
- Acquirer's direct holding increased from 13.18% (7.30 Cr shares) to 14.09% (7.80 Cr shares)
- Combined promoter and PAC holding crossed 30%, rising from 29.98% to 30.88% (17.10 Cr shares)
- Total equity share capital stands at Rs 55,37,19,700 across 55,37,19,700 equity shares of Re. 1 each
Genpharmasec Ltd has scheduled a Board of Directors meeting on September 2, 2026, to finalize administrative matters concerning its 34th Annual General Meeting (AGM) for the fiscal year ended March 31, 2026. Key agenda items include approving the draft notice, setting the AGM date and mode, fixing the e-voting cut-off dates, and approving the FY26 Directors' Report and Annual Report. The board will also approve the closure of share transfer books and appoint a scrutinizer for e-voting. This is a standard compliance procedure with no immediate impact on business operations or financials.
- Board meeting scheduled for September 02, 2026
- Agenda to approve Notice and Calendar of Events for the 34th Annual General Meeting
- Board to review and approve the Directors' Report and Annual Report for FY2025-26
- To fix cut-off date and timeline for member e-voting rights
Genpharmasec Ltd has entered into a non-exclusive Super Stockist agreement with Amneal Healthcare Private Limited (AHPL), a subsidiary of the US-based Amneal Pharmaceuticals. Under the terms, AHPL has provided a minimum annual sales commitment of approximately ₹75 Crores for each calendar year. This is a highly material development for Genpharmasec, as the commitment value exceeds its current net worth of ₹71 Crores. The company will distribute AHPL's products to wholesale and retail pharmacists across specified territories.
- Minimum annual sales commitment of approximately ₹75 Crores per calendar year.
- The commitment value of ₹75 Cr represents approximately 105.6% of the company's current net worth of ₹71 Cr.
- Partner AHPL is part of Amneal Pharmaceuticals, which has invested over $300 million in India over the last 15 years.
- Genpharmasec will act as a non-exclusive Super Stockist for products manufactured by AHPL and its third-party licensors.
- The agreement marks a significant scale-up from the company's existing diagnostic equipment distribution business.
Genpharmasec Ltd has confirmed zero deviation in the utilization of ₹4,845.05 Lakhs raised through its Rights Issue allotted on February 21, 2024. As of June 30, 2026, the company has fully utilized funds for the acquisition of Derren Healthcare (₹14.43 Cr), working capital (₹16.50 Cr), and general corporate purposes (₹11.38 Cr). A portion of the debt repayment allocation remains, with ₹2.89 Cr spent against an original allocation of ₹5.88 Cr. The Audit Committee has reviewed and confirmed that all funds are being deployed as per the original Letter of Offer.
- Total funds raised via Rights Issue on February 21, 2024, amounted to ₹4,845.05 Lakhs.
- ₹1,443.58 Lakhs fully utilized to acquire equity shares of Derren Healthcare Private Limited.
- ₹1,650.00 Lakhs fully deployed towards meeting working capital requirements.
- ₹289.00 Lakhs utilized for debt repayment out of the allocated ₹588.00 Lakhs as of June 30, 2026.
- Zero deviation or variation reported across all five primary objects of the issue.
Genpharmasec reported a sharp decline in consolidated net profit to ₹0.23 Cr for Q1 FY27, down from ₹1.22 Cr in the same quarter last year. While consolidated revenue grew 313% YoY to ₹49.71 Cr, it declined 10% sequentially from the March 2026 quarter. The bottom line was severely pressured by losses in the Manufacturing & Processing segment (₹1.25 Cr loss) and Laboratory Testing (₹0.29 Cr loss), which offset the ₹2.22 Cr profit from the core Pharmaceutical trading business.
- Consolidated Revenue increased 313% YoY to ₹49.71 Cr from ₹12.04 Cr in June 2025.
- Consolidated Net Profit fell 81% YoY to ₹0.23 Cr compared to ₹1.22 Cr in the previous year's quarter.
- Manufacturing & Processing segment reported a significant loss of ₹1.25 Cr on revenue of ₹2.72 Cr.
- Pharmaceutical segment remains the sole profit driver with a segment result of ₹2.22 Cr.
- Total Comprehensive Income for the group turned into a marginal loss of ₹0.58 Lakhs after accounting for non-controlling interests.
Genpharmasec reported a sharp increase in consolidated revenue to ₹49.71 Cr for Q1 FY27, up from ₹12.04 Cr in Q1 FY26, driven primarily by the Pharmaceutical segment. However, consolidated net profit fell to ₹0.23 Cr from ₹1.22 Cr in the year-ago period, largely due to losses in the Manufacturing & Processing division. The core Pharmaceutical segment remains the primary profit driver with a segment PBT of ₹2.22 Cr. Standalone performance was relatively stable with a PAT of ₹1.57 Cr, but consolidated results were weighed down by non-core segment underperformance.
- Consolidated Revenue from operations grew 313% YoY to ₹49.71 Cr in Q1 FY27.
- Pharmaceutical segment contributed ₹44.78 Cr to revenue, representing 90% of total consolidated turnover.
- Manufacturing & Processing segment reported a loss of ₹1.25 Cr at the PBT level, acting as a major drag on consolidated earnings.
- Consolidated Net Profit attributable to the parent company stood at ₹0.26 Cr, a significant decline from ₹1.22 Cr in Q1 FY26.
- Standalone PAT remained flat at ₹1.57 Cr compared to ₹1.56 Cr in the previous year's quarter.
Genpharmasec Ltd has scheduled a board meeting for August 11, 2026, to approve its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company is coming off a high-growth year where FY26 revenue reached Rs 131 Cr, a significant jump from Rs 33 Cr in FY25. However, operating margins remain thin at 1.9%, and the stock is currently trading at a low price of Rs 1.0 with a market cap of Rs 63 Cr. The trading window for insiders has been closed since July 01, 2026.
- Board meeting scheduled for August 11, 2026, to approve Q1 FY27 results
- Trading window closed from July 01, 2026, until 48 hours post-announcement
- Company reported a significant revenue increase to Rs 131.0 Cr in FY26
- Operating profit margin (TTM) stands at a narrow 1.9%
- Promoter holding remains stable at 29.98% as of June 2026
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
